• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

    2/14/24 3:00:03 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRS alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3 )*

                

    Coherus Biosciences Inc


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    19249H103


    (CUSIP Number)

    December 31, 2023


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 19249H103

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    AllianceBernstein L.P.
    13-4064930
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [X]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 156,000
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 156,000
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    156,000
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [X]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.1%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Coherus Biosciences Inc
    (b) Address of Issuer's Principal Executive Offices
    333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA 94065
    Item 2.
    (a) Name of Person Filing
    AllianceBernstein L.P. ("AllianceBernstein L.P.")
    (b) Address of Principal Business Office or, if None, Residence
    501 Commerce Street, Nashville, TN 37203

    All media outlets, please contact Jennifer Will at AllianceBernstein (212-969-1157) with any questions. All other questions can be directed to [email protected].
    (c) Citizenship
    Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    19249H103
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    156,000 shares acquired solely for investment purposes on behalf of client discretionary investment advisory accounts.*
    (b) Percent of Class:
    0.1%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 156,000
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 156,000
    (iv) shared power to dispose or to direct the disposition of 0
    *AllianceBernstein L.P. is a majority owned subsidiary of Equitable Holdings, Inc. ("EQH"). AllianceBernstein operates under independent management and makes independent decisions from EQH and its respective subsidiaries, and EQH calculates and reports beneficial ownership separately from AllianceBernstein pursuant to guidance provided by the Securities and Exchange Commission in Release Number 34-39538 (January 12, 1998).
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    AllianceBernstein L.P.
    By: /s/ Melissa Guerra
    Date: February 14, 2024
    Name: Melissa Guerra
    Title: Vice President

    Get the next $CHRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHRS

    DatePrice TargetRatingAnalyst
    8/16/2024$4.00 → $1.50Buy → Neutral
    UBS
    11/17/2023$11.00Outperform
    Robert W. Baird
    11/8/2023Buy → Hold
    Maxim Group
    7/24/2023$12.00Buy
    Citigroup
    5/1/2023$24.00Buy
    Truist
    3/28/2023$11.00Neutral → Buy
    UBS
    6/14/2022$7.00Neutral
    UBS
    3/7/2022$15.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

      5/22/24 9:41:01 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

      4/23/24 4:41:07 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

      12/27/23 4:38:39 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

      REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ((Coherus Oncology, NASDAQ:CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. "The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a significant player in this dynamic space and unlock the potential of these next-generation therapeutic approaches," said Jill O'Donnell-Tormey, Ph.D., Coherus Oncology board member. Dr. O'Donnell-Torme

      5/30/25 8:00:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

      REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ("STORM") to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma and endometrial cancer. "We are excited to partner with STORM on the development of the LOQTORZI/STC-15 combination, with patient dosing underway in the Phase 1b/2 study," said Theresa LaVallee, Ph.D., Chief Scientific and Development Officer of Coher

      5/27/25 8:30:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

      – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 12, 2025 (GLOBE N

      5/12/25 4:15:13 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Coherus BioSciences downgraded by UBS with a new price target

      UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously

      8/16/24 7:33:26 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Coherus BioSciences with a new price target

      Robert W. Baird initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $11.00

      11/17/23 7:37:50 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences downgraded by Maxim Group

      Maxim Group downgraded Coherus BioSciences from Buy to Hold

      11/8/23 9:19:04 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wahlstrom Mats sold $73,881 worth of shares (99,988 units at $0.74) (SEC Form 4)

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/28/25 5:12:50 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:59:16 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Lanfear Dennis M

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:58:02 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Coherus BioSciences Inc.

      SC 13G - Coherus BioSciences, Inc. (0001512762) (Subject)

      11/13/24 4:30:25 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      7/23/24 8:23:56 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      5/22/24 7:27:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Leadership Updates

    Live Leadership Updates

    See more

    $CHRS
    SEC Filings

    See more
    • Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

      REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou

      6/5/24 9:00:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

       – Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec

      7/20/23 4:04:53 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

      - Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of cancer immunotherapy leader Jill O'Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O'Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Board of Directors. Dr. O'Donnell-Tormey is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute ("CRI"), a nonprofit organization dedicated exclusively to

      5/11/22 6:00:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Coherus Oncology, Inc. (0001512762) (Filer)

      5/30/25 4:05:26 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC TO-I/A filed by Coherus BioSciences Inc.

      SC TO-I/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      5/15/25 4:46:03 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Coherus BioSciences Inc.

      10-Q - Coherus BioSciences, Inc. (0001512762) (Filer)

      5/12/25 4:59:11 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Financials

    Live finance-specific insights

    See more
    • Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

      – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 12, 2025 (GLOBE N

      5/12/25 4:15:13 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

      REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference call, please pre-register through

      5/5/25 4:01:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

      – CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced data from its ongoing Phase 1

      4/28/25 10:10:11 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care